FDA names renowned oncologist Dr. Pazdur to lead drug evaluation division
The US Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur as the new head of its Center for Drug Evaluation and Research (CDER). Dr. Pazdur, a renowned oncologist, takes over from Dr. George Tidmarsh, who resigned following personal conduct reviews and a defamation lawsuit.
Dr. Pazdur brings an impressive track record to the role. He has been recognized with numerous awards, including being named one of the 50 World's Greatest Leaders by Fortune magazine in 2015. He has authored over 800 articles, abstracts, and book chapters, and written two medical oncology textbooks. Dr. Pazdur will continue to lead the FDA's Oncology Center of Excellence, a role he has held since 2017, until a successor is chosen.
Dr. Marty Makary, FDA Commissioner, praised Dr. Pazdur's forward-thinking approach to science. However, the search for a permanent successor to lead the Oncology Center of Excellence is ongoing, with no details yet on a succession process.
Dr. Pazdur's appointment comes at a time of regulatory reforms in the CDER, which oversees the safety and regulation of most prescription drugs and over-the-counter medicines, among other products. His expertise and leadership are expected to guide the CDER through these changes.
